Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCRGet Free Report) has been given an average rating of “Moderate Buy” by the nine analysts that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, seven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $68.6667.

A number of equities analysts recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a report on Wednesday, October 8th. Guggenheim lowered their price objective on shares of Structure Therapeutics from $92.00 to $90.00 and set a “buy” rating for the company in a research note on Thursday, August 7th. HC Wainwright cut their target price on shares of Structure Therapeutics from $75.00 to $60.00 and set a “buy” rating on the stock in a research note on Thursday, August 7th. JMP Securities reduced their target price on shares of Structure Therapeutics from $89.00 to $87.00 and set a “market outperform” rating on the stock in a report on Thursday, August 7th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $65.00 price target on shares of Structure Therapeutics in a research note on Monday, June 23rd.

Read Our Latest Stock Analysis on GPCR

Institutional Investors Weigh In On Structure Therapeutics

Several large investors have recently bought and sold shares of GPCR. State of Wyoming acquired a new stake in Structure Therapeutics in the 2nd quarter valued at about $28,000. National Bank of Canada FI raised its holdings in Structure Therapeutics by 1,448.2% in the first quarter. National Bank of Canada FI now owns 2,957 shares of the company’s stock valued at $51,000 after acquiring an additional 2,766 shares in the last quarter. Assetmark Inc. raised its holdings in Structure Therapeutics by 39.9% in the second quarter. Assetmark Inc. now owns 2,877 shares of the company’s stock valued at $60,000 after acquiring an additional 820 shares in the last quarter. ANTIPODES PARTNERS Ltd grew its holdings in Structure Therapeutics by 310.7% during the 1st quarter. ANTIPODES PARTNERS Ltd now owns 4,247 shares of the company’s stock worth $74,000 after acquiring an additional 3,213 shares in the last quarter. Finally, PNC Financial Services Group Inc. increased its position in shares of Structure Therapeutics by 29.1% in the 2nd quarter. PNC Financial Services Group Inc. now owns 4,415 shares of the company’s stock valued at $92,000 after purchasing an additional 994 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Stock Performance

Structure Therapeutics stock opened at $27.38 on Friday. The company has a market capitalization of $1.58 billion, a PE ratio of -26.08 and a beta of -1.65. Structure Therapeutics has a fifty-two week low of $13.22 and a fifty-two week high of $42.57. The firm has a 50 day moving average price of $22.99 and a 200 day moving average price of $21.59.

Structure Therapeutics (NASDAQ:GPCRGet Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.08). As a group, equities research analysts forecast that Structure Therapeutics will post -0.82 earnings per share for the current year.

Structure Therapeutics Company Profile

(Get Free Report)

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

Read More

Analyst Recommendations for Structure Therapeutics (NASDAQ:GPCR)

Receive News & Ratings for Structure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Structure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.